119 related articles for article (PubMed ID: 10228494)
1. Serum-soluble E-cadherin fragments in lung cancer.
Cioffi M; Gazzerro P; Di Finizio B; Vietri MT; Di Macchia C; Puca GA; Molinari AM
Tumori; 1999; 85(1):32-4. PubMed ID: 10228494
[TBL] [Abstract][Full Text] [Related]
2. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
3. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers.
Gogali A; Charalabopoulos K; Zampira I; Konstantinidis AK; Tachmazoglou F; Daskalopoulos G; Constantopoulos SH; Dalavanga Y
Chest; 2010 Nov; 138(5):1173-9. PubMed ID: 20495107
[TBL] [Abstract][Full Text] [Related]
4. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group.
Rastel D; Ramaioli A; Cornillie F; Thirion B
Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
6. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of neuron-specific enolase, carbohydrate antigen 19-9 and carbohydrate antigen 125 in carcinoma of the lung.
Oktay G; Güner G; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1995 May; 23(2):211S. PubMed ID: 7672232
[No Abstract] [Full Text] [Related]
8. The relationship between the serum intercellular adhesion molecule-1 level and the prognosis of the disease in lung cancer.
Shin HS; Jung CH; Park HD; Lee SS
Korean J Intern Med; 2004 Mar; 19(1):48-52. PubMed ID: 15053044
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer.
Choi YS; Shim YM; Kim SH; Son DS; Lee HS; Kim GY; Han J; Kim J
Eur J Cardiothorac Surg; 2003 Sep; 24(3):441-9. PubMed ID: 12965318
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers and IL-2R in lung cancer.
Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
[TBL] [Abstract][Full Text] [Related]
11. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of serum soluble interleukin-2 receptors in lung cancer.
Yano T; Yoshino I; Yokoyama H; Fukuyama Y; Takai E; Asoh H; Ichinose Y
Lung Cancer; 1996 Aug; 15(1):79-84. PubMed ID: 8865125
[TBL] [Abstract][Full Text] [Related]
13. Elastase levels in small and non-small cell lung carcinoma.
Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
[No Abstract] [Full Text] [Related]
14. c-erbB-2 protein in serum of primary lung cancer patients.
Filiberti R; Marroni P; Paganuzzi M; Izzo V; Padovani P; Cafferata M; Ardizzoni A; Neri M; Raimondi L; Puntoni R
Cancer Detect Prev; 2002; 26(1):64-8. PubMed ID: 12088205
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum beta-defensins concentrations in patients with lung cancer.
Arimura Y; Ashitani J; Yanagi S; Tokojima M; Abe K; Mukae H; Nakazato M
Anticancer Res; 2004; 24(6):4051-7. PubMed ID: 15736451
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
17. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
18. Development of an AlphaLISA assay to quantify serum core-fucosylated E-cadherin as a metastatic lung adenocarcinoma biomarker.
Wen CL; Chen KY; Chen CT; Chuang JG; Yang PC; Chow LP
J Proteomics; 2012 Jul; 75(13):3963-76. PubMed ID: 22634079
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.
Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB
Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
